CoChat
Sign Up
Cited by 357

The DOI matches its Crossref record.

Colorectal cancer in inflammatory bowel disease: The risk, pathogenesis, prevention and diagnosis

Kim, Eun Ran·2014·World Journal of Gastroenterology
DOI 10.3748/wjg.v20.i29.9872
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3748/wjg.v20.i29.9872

Cites

Statistics

Figures

Figure 1 Molecular pathogenesis of sporadic colon cancer and colon cancer associated with inflammatory bowel disease. Many of the genetic alterations associated with development of sporadic colon cancer also play a role in colitis associated colon cancer. However, the frequency and sequence of these events differ between the cancers. Modified from Ref [21]. APC: Adenomatous polyposis coli; MSI: Microsatellite instability; KAS : Kirsten Rat Sarcoma Viral Oncogene Homolog; COX-2: Cyclooxygenase-2; DCC: Deleted in colorectal carcinoma; DPC4: Deleted in pancreatic carcinoma 4; CIN: Chromosomal instability.
Figure 1 Molecular pathogenesis of sporadic colon cancer and colon cancer associated with inflammatory bowel disease. Many of the genetic alterations associated with development of sporadic colon cancer also play a role in colitis associated colon cancer. However, the frequency and sequence of these events differ between the cancers. Modified from Ref [21]. APC: Adenomatous polyposis coli; MSI: Microsatellite instability; KAS : Kirsten Rat Sarcoma Viral Oncogene Homolog; COX-2: Cyclooxygenase-2; DCC: Deleted in colorectal carcinoma; DPC4: Deleted in pancreatic carcinoma 4; CIN: Chromosomal instability.CC-BY-NC · From the PDF
Image 2
CC-BY-NC · From the PDF
Image 3
CC-BY-NC · From the PDF
Image 4
CC-BY-NC · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 98

  1. 10.1002/jso.21505 · DOI
  2. 10.1053/j.gastro.2005.12.037 · DOI
  3. 10.1002/ibd.21365 · DOI
  4. 10.1111/j.1572-0241.2006.00520.x · DOI
  5. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48:526-535. · DOI
  6. Winther KV, Jess T, Langholz E, Munkholm P, Binder V. Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol 2004;2:1088-1095. · DOI
  7. Kim BJ, Yang SK, Kim JS, Jeen YT, Choi H, Han DS, Kim HJ, Kim WH, Kim JY, Chang DK. Trends of ulcerative colitis-associated colorectal cancer in Korea: A KASID study. J Gastroenterol Hepatol 2009;24:667-671. · DOI
  8. Söderlund S, Brandt L, Lapidus A, Karlén P, Broström O, Löfberg R, Ekbom A, Askling J. Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease. Gastroenterology 2009;136:1561-157; quiz 1818-9. · DOI
  9. 10.1111/j.1365-2036.2006.02854.x · DOI
  10. Lakatos PL, Lakatos L. Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World J Gastroenterol 2008;14:3937-3947. · DOI
  11. 10.1038/ajg.2013.249 · DOI
  12. 10.5009/gnl.2008.2.2.61 · DOI
  13. 10.1056/nejm199011013231802 · DOI
  14. 10.1097/01.MIB.0000217770.21261.ce · DOI
  15. 10.1002/hep.24247 · DOI
  16. 10.1136/gut.2004.046615 · DOI · Paper page
  17. Olsson R, Danielsson A, Järnerot G, Lindström E, Lööf L, Rolny P, Rydén BO, Tysk C, Wallerstedt S. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology 1991;100:1319-1323. · DOI
  18. Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002;56:48-54. · DOI · Paper page
  19. Nuako KW, Ahlquist DA, Mahoney DW, Schaid DJ, Siems DM, Lindor NM. Familial predisposition for colorectal cancer in chronic ulcerative colitis: a case-control study. Gastroenterology 1998;115:1079-1083. · DOI
  20. Askling J, Dickman PW, Karlén P, Broström O, Lapidus A, Löfberg R, Ekbom A. Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology 2001;120:1356-1362. · DOI
  21. 10.1053/j.gastro.2011.01.057 · DOI
  22. 10.1152/ajpgi.00079.2004 · DOI
  23. Rutter M, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm M, Williams C, Price A, Talbot I, Forbes A. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004;126:451-459. · DOI · Paper page
  24. 10.1053/j.gastro.2007.08.001 · DOI
  25. 10.1053/j.gastro.2006.03.028 · DOI
  26. 10.1097/MEG.0b013e32835b5803 · DOI
  27. Triantafillidis JK, Nasioulas G, Kosmidis PA. Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies. Anticancer Res 2009;29:2727-2737.
  28. 10.1016/j.coph.2009.06.006 · DOI
  29. Befrits R, Hammarberg C, Rubio C, Jaramillo E, Tribukait B. DNA aneuploidy and histologic dysplasia in long-standing ulcerative colitis. A 10-year follow-up study. Dis Colon Rectum 1994;37:313-319; discussion 319-320. · DOI
  30. Willenbucher RF, Zelman SJ, Ferrell LD, Moore DH, Waldman FM. Chromosomal alterations in ulcerative colitis-related neoplastic progression. Gastroenterology 1997;113:791-801. · DOI
  31. Hardy RG, Meltzer SJ, Jankowski JA. ABC of colorectal cancer. Molecular basis for risk factors. BMJ 2000;321:886-889. · DOI
  32. Itzkowitz S. Colon carcinogenesis in inflammatory bowel disease: applying molecular genetics to clinical practice. J Clin Gastroenterol 2003;36:S70-S74; discussion S94-96. · DOI
  33. Aust DE, Terdiman JP, Willenbucher RF, Chang CG, Molinaro-Clark A, Baretton GB, Loehrs U, Waldman FM. The APC/beta-catenin pathway in ulcerative colitis-related colorectal carcinomas: a mutational analysis. Cancer 2002;94:1421-1427. · DOI
  34. Tarmin L, Yin J, Harpaz N, Kozam M, Noordzij J, Antonio LB, Jiang HY, Chan O, Cymes K, Meltzer SJ. Adenomatous polyposis coli gene mutations in ulcerative colitis-associated dysplasias and cancers versus sporadic colon neoplasms. Cancer Res 1995;55:2035-2038.
  35. 10.1007/s13402-010-0006-4 · DOI
  36. 10.1200/jco.2007.10.9744 · DOI
  37. Schulmann K, Mori Y, Croog V, Yin J, Olaru A, Sterian A, Sato F, Wang S, Xu Y, Deacu E. Molecular phenotype of inflammatory bowel disease-associated neoplasms with microsatellite instability. Gastroenterology 2005;129:74-85. · DOI
  38. Fleisher AS, Esteller M, Harpaz N, Leytin A, Rashid A, Xu Y, Liang J, Stine OC, Yin J, Zou TT. Microsatellite instability in inflammatory bowel disease-associated neoplastic lesions is associated with hypermethylation and diminished expression of the DNA mismatch repair gene, hMLH1. Cancer Res 2000;60:4864-4868.
  39. Hsieh CJ, Klump B, Holzmann K, Borchard F, Gregor M, Porschen R. Hypermethylation of the p16INK4a promoter in colectomy specimens of patients with long-standing and extensive ulcerative colitis. Cancer Res 1998;58:3942-3945.
  40. Smalley WE, DuBois RN. Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv Pharmacol 1997;39:1-20. · DOI
  41. Elzagheid A, Emaetig F, Alkikhia L, Buhmeida A, Syrjänen K, El-Faitori O, Latto M, Collan Y, Pyrhönen S. High cyclooxygenase-2 expression is associated with advanced stages in colorectal cancer. Anticancer Res 2013;33:3137-3143.
  42. 10.1146/annurev.pharmtox.42.082301.164620 · DOI
  43. 10.1016/s0002-9440(10)64587-7 · DOI
  44. 10.1038/ejhg.2010.159 · DOI
  45. 10.1152/ajpcell.00422.2001 · DOI
  46. Klaunig JE, Xu Y, Isenberg JS, Bachowski S, Kolaja KL, Jiang J, Stevenson DE, Walborg EF. The role of oxidative stress in chemical carcinogenesis. Environ Health Perspect 1998;106 Suppl 1:289-295. · DOI
  47. Hussain SP, Amstad P, Raja K, Ambs S, Nagashima M, Bennett WP, Shields PG, Ham AJ, Swenberg JA, Marrogi AJ. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res 2000;60:3333-3337.
  48. Kimura H, Hokari R, Miura S, Shigematsu T, Hirokawa M, Akiba Y, Kurose I, Higuchi H, Fujimori H, Tsuzuki Y. Increased expression of an inducible isoform of nitric oxide synthase and the formation of peroxynitrite in colonic mucosa of patients with active ulcerative colitis. Gut 1998;42:180-187. · DOI
  49. Rachmilewitz D, Stamler JS, Bachwich D, Karmeli F, Ackerman Z, Podolsky DK. Enhanced colonic nitric oxide generation and nitric oxide synthase activity in ulcerative colitis and Crohn’s disease. Gut 1995;36:718-723. · DOI
  50. Actis GC, Tarallo S, Rosina F. Cutting edge: chemoprevention of colorectal neoplasia in inflammatory bowel disease. Inflamm Allergy Drug Targets 2013;12:1-7. · DOI
  51. 10.1016/s0002-9440(10)61172-8 · DOI
  52. 10.1172/jci118861 · DOI
  53. O’Mahony L, Feeney M, O’Halloran S, Murphy L, Kiely B, Fitzgibbon J, Lee G, O’Sullivan G, Shanahan F, Collins JK. Probiotic impact on microbial flora, inflammation and tumour development in IL-10 knockout mice. Aliment Pharmacol Ther 2001;15:1219-1225. · DOI
  54. 10.1053/j.gastro.2008.02.012 · DOI
  55. Pinczowski D, Ekbom A, Baron J, Yuen J, Adami HO. Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. Gastroenterology 1994;107:117-120. · DOI
  56. 10.1016/j.bpg.2011.09.003 · DOI
  57. 10.1111/j.1572-0241.2005.41442.x · DOI
  58. 10.1002/ibd.20074 · DOI
  59. 10.1038/ajg.2011.50 · DOI
  60. 10.1136/gut.2011.237412 · DOI
  61. Lashner BA, Provencher KS, Seidner DL, Knesebeck A, Brzezinski A. The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. Gastroenterology 1997;112:29-32. · DOI
  62. Matula S, Croog V, Itzkowitz S, Harpaz N, Bodian C, Hossain S, Ullman T. Chemoprevention of colorectal neoplasia in ulcerative colitis: the effect of 6-mercaptopurine. Clin Gastroenterol Hepatol 2005;3:1015-1021. · DOI
  63. 10.3748/wjg.v18.i29.3839 · DOI
  64. 10.1053/gast.2003.50156 · DOI
  65. Tung BY, Emond MJ, Haggitt RC, Bronner MP, Kimmey MB, Kowdley KV, Brentnall TA. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001;134:89-95. · DOI
  66. 10.1038/ajg.2011.156 · DOI
  67. Biasco G, Di Marco MC. Folate and prevention of colorectal cancer in ulcerative colitis. Eur J Cancer Prev 2005;14:395-398. · DOI
  68. Baggott JE, Morgan SL, Ha T, Vaughn WH, Hine RJ. Inhibition of folate-dependent enzymes by non-steroidal anti-inflammatory drugs. Biochem J 1992;282:197-202. · DOI
  69. Reisenauer AM, Halsted CH. Human jejunal brush border folate conjugase. Characteristics and inhibition by salicylazosulfapyridine. Biochim Biophys Acta 1981;659:62-69. · DOI
  70. Diculescu M, Ciocîrlan M, Ciocîrlan M, Piţigoi D, Becheanu G, Croitoru A, Spanache S. Folic acid and sulfasalazine for colorectal carcinoma chemoprevention in patients with ulcerative colitis: the old and new evidence. Rom J Gastroenterol 2003;12:283-286.
  71. 10.1038/ajg.2010.428 · DOI
  72. Takashi H, Tmomyuki K, Yukihide K. Colorectal cancer in patients with inflammatory bowel disease in Japan. Stomach Intestine 2002;37:887-893.
  73. 10.1097/MIB.0b013e3182802c6a · DOI
  74. 10.1002/14651858.CD000279.pub3 · DOI
  75. 10.1002/14651858.CD000279.pub2 · DOI
  76. 10.1136/gut.2010.225466 · DOI
  77. 10.1016/j.crohns.2007.12.001 · DOI
  78. 10.1053/j.gastro.2009.12.035 · DOI
  79. 10.1038/ajg.2009.727 · DOI
  80. 10.5946/ce.2012.45.3.274 · DOI
  81. 10.1038/ajg.2011.93 · DOI
  82. Rubin CE, Haggitt RC, Burmer GC, Brentnall TA, Stevens AC, Levine DS, Dean PJ, Kimmey M, Perera DR, Rabinovitch PS. DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology 1992;103:1611-1620. · DOI
  83. 10.1053/j.gastro.2007.01.048 · DOI
  84. 10.1053/j.gastro.2005.12.035 · DOI
  85. 10.1016/j.gie.2009.05.010 · DOI
  86. van Rijn AF, Fockens P, Siersema PD, Oldenburg B. Adherence to surveillance guidelines for dysplasia and colorectal carcinoma in ulcerative and Crohn’s colitis patients in the Netherlands. World J Gastroenterol 2009;15:226-230. · DOI
  87. Eaden JA, Ward BA, Mayberry JF. How gastroenterologists screen for colonic cancer in ulcerative colitis: an analysis of performance. Gastrointest Endosc 2000;51:123-128. · DOI
  88. 10.4253/wjge.v4.i4.108 · DOI
  89. 10.1111/apt.12508 · DOI
  90. Rutter MD, Saunders BP, Schofield G, Forbes A, Price AB, Talbot IC. Pancolonic indigo carmine dye spraying for the detection of dysplasia in ulcerative colitis. Gut 2004;53:256-260. · DOI
  91. 10.1111/j.1572-0241.2008.01934.x · DOI
  92. 10.1053/gast.2003.50146 · DOI
  93. 10.1055/s-2007-966214 · DOI
  94. 10.1055/s-0030-1255956 · DOI
  95. 10.1038/ajg.2012.67 · DOI
  96. 10.1136/gut.2007.131359 · DOI
  97. Messmann H, Endlicher E, Freunek G, Rümmele P, Schölmerich J, Knüchel R. Fluorescence endoscopy for the detection of low and high grade dysplasia in ulcerative colitis using systemic or local 5-aminolaevulinic acid sensitisation. Gut 2003;52:1003-1007. · DOI
  98. 10.1136/gut.2007.144097 · DOI

Cited by

Sorted by citations

Metadata

Authors
Kim, E. R.
Venue
World Journal of Gastroenterology
Publisher
Baishideng Publishing Group Inc.
Published
2014
Volume
20
Issue
29
Pages
9872
ISSN
1007-9327
DOI
10.3748/wjg.v20.i29.9872
Cited by
357
References
0
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review